Aktienanalyse zu Delcath Systems Inc (DCTH)DCTHDelcath Systems Inc

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT comprises the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA). It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Delcath Systems Inc is a good buy right now, trading at $14.42 with a strong revenue growth forecast. The company raised its 2026 revenue guidance to $104-$108 million, indicating confidence in future performance. Additionally, the gross margin has improved to 89.75% in Q2 2026, reflecting efficient operations. However, the current RSI of 36.895 suggests the stock is nearing oversold territory, which could present a buying opportunity. The main risk is the high forward P/E ratio of 232.56, indicating that the stock may be overvalued if growth does not meet expectations.